We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sepragen Announces Intent to Acquire Assets of Cytobiologics
News

Sepragen Announces Intent to Acquire Assets of Cytobiologics

Sepragen Announces Intent to Acquire Assets of Cytobiologics
News

Sepragen Announces Intent to Acquire Assets of Cytobiologics

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sepragen Announces Intent to Acquire Assets of Cytobiologics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sepragen Corporation have announced the signing of a letter of intent to acquire substantially all of the assets of Cytobiologics, Inc., a development stage company.

The assets include laboratory equipment and intellectual property related to certain rapid assays and a high density bioreactor, which complements Sepragen's existing high density bioreactor currently in "alpha development."

Sepragen's CEO and founder, Vinit Saxena, remarked, "The addition of Cytobiologics' capability will provide us with facilities, talent and intellectual property to pursue the development of an integrated bio-manufacturing system. This will allow us to move up the value chain and be more of a full solution provider to our customers. The acquisition is subject to concluding a definitive agreement and to securing board approvals."

Sepragen currently provides innovative bio-purification products that enable biotech companies to develop and produce biopharmaceuticals quickly and cost-effectively. Sepragen products are used world-wide by leading biotech companies to manufacture over a dozen FDA approved drugs.

Advertisement